Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24
|
作者：
Vogel, AM
Lennon, DR
Broadbent, R
Byrnes, CA
Grimwood, K
Mildenhall, L
Richardson, V
Rowley, S
机构：
[1] Univ Auckland, Wellington, New Zealand
[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand
[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand
[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand
来源：
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期
关键词：
consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;
D O I：
10.1046/j.1440-1754.2002.00057.x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.
引用
收藏
页码：550 / 554
页数：5
相关论文
共 50 条
  • [1] Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
    Mejias, Asuncion
    Ramilo, Octavio
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03) : 433 - 439
  • [2] Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis
    Lolfand, JH
    Touch, SM
    O'Connor, JP
    Chatterton, ML
    Moxey, ED
    Paddock, LE
    Nash, DB
    Desai, SA
    CLINICAL THERAPEUTICS, 2000, 22 (11) : 1357 - 1369
  • [3] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    Null, D
    Bimle, C
    Weisman, L
    Johnson, K
    Steichen, J
    Singh, S
    Wang, E
    Asztalos, E
    Loeffler, AM
    Azimi, PH
    Lieberman, JM
    O'Donnell, NE
    Cooke, RJ
    McCormick, K
    Koo, W
    Hammami, M
    Milner, AD
    Gaon, P
    Nachman, S
    Tarpey, KP
    Sánchez, PJ
    Broyles, RS
    Bratcher, D
    Ball, MV
    Duda, FJ
    DeCuir, PM
    Pollara, B
    Nelson, LS
    Balbus, M
    Schultz, MJ
    Chipps, BE
    Givner, LB
    O'Shea, M
    Everard, M
    Pfeffer, K
    Page, AJ
    Dennehy, PH
    Modlin, J
    Rhodes, T
    DeVincenzo, N
    Nickerson, B
    Arrieta, A
    Boucher, FD
    Keeney, RE
    Young, TE
    Stevens, JC
    Ariagno, R
    Adams, M
    Polak, MJ
    Lynch, SK
    PEDIATRICS, 1998, 102 (03) : 531 - 537
  • [4] Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
    Viguria, Natividad
    Navascues, Ana
    Juanbeltz, Regina
    Echeverria, Alberto
    Ezpeleta, Carmen
    Castilla, Jesus
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (06) : 1867 - 1872
  • [5] Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab
    Meissner, HC
    Rennels, MB
    Pickering, LK
    Hall, CB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (03) : 284 - 285
  • [6] Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants
    Singleton, R
    Dooley, L
    Bruden, D
    Raelson, S
    Butler, JC
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (06) : 540 - 545
  • [7] Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
    Calomfirescu-Avramescu, Andreea
    Toma, Adrian Ioan
    Mehedintu, Claudia
    Nastase, Leonard
    Dima, Vlad
    VACCINES, 2025, 13 (02)
  • [8] Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants
    Ashkenazi-Hoffnung, Liat
    Dotan, Miri
    Livni, Gilat
    Amir, Jacob
    Bilavsky, Efraim
    AMERICAN JOURNAL OF INFECTION CONTROL, 2014, 42 (09) : 991 - 995
  • [9] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Candice Bjornson
    Parco Chan
    Abby Li
    Bosco Paes
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
  • [10] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson, Candice
    Chan, Parco
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    Mitchell, Ian
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (06) : 1113 - 1118
12345